<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preterm prelabor rupture of membranes: Clinical manifestations and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preterm prelabor rupture of membranes: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preterm prelabor rupture of membranes: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Duff, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prelabor rupture of membranes (PROM) refers to fetal membrane rupture before the onset of uterine contractions. Preterm PROM (PPROM) refers to PROM before 37+0 weeks of gestation. It is responsible for, or associated with, approximately one-third of preterm births and is the single most common identifiable factor associated with preterm birth. </p><p>The epidemiology, pathogenesis, clinical manifestations, diagnosis, and clinical course of PROM at approximately 23 to 37 weeks of gestation will be discussed here. Management of PROM at 23 to 37 weeks, as well as PROM before and after this gestational age range, are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/120959.html" rel="external">"Preterm prelabor rupture of membranes: Management and outcome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6741.html" rel="external">"Prelabor rupture of membranes before and at the limit of viability"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6757.html" rel="external">"Prelabor rupture of membranes at term: Management"</a>.)</p><p></p><p class="headingAnchor" id="H450397439"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Approximately 3 percent of pregnancies &lt;37 weeks are complicated by PPROM. By gestational age, approximately 0.5 percent of PROM occurs at &lt;27 weeks, 1 percent occurs at 27 to 34 weeks, and 1 percent occurs at 34 to 37 weeks [<a href="#rid1">1-3</a>]. </p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of spontaneous membrane rupture is not completely understood. The strength and integrity of fetal membranes derive from extracellular membrane proteins, including collagens, fibronectin, and laminin, whereas matrix metalloproteases (MMPs) decrease membrane strength by increasing collagen degradation [<a href="#rid4">4</a>]. A variety of pathologic events (eg, subclinical or overt infection, inflammation, mechanical stress, bleeding) can disrupt these and other homeostatic processes and initiate a cascade of biochemical changes that culminate in PROM [<a href="#rid5">5</a>]. Although the pathway varies depending on the initiating event (which is not always identifiable), it is likely that all pathways lead to a final common pathway ending in membrane rupture. (See  <a class="medical medical_review" href="/d/html/6785.html" rel="external">"Spontaneous preterm birth: Pathogenesis"</a>.)</p><p class="headingAnchor" id="H3816511981"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>A variety of risk factors predispose to development of PPROM. These risk factors are similar to those for preterm labor  (<a class="graphic graphic_table graphicRef68992" href="/d/graphic/68992.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis"</a>). However, many patients have no obvious identifiable risk factor.</p><p>A history of PPROM in a previous pregnancy, genital tract infection, antepartum bleeding, and cigarette smoking have a particularly strong association with PPROM and are discussed below [<a href="#rid6">6</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genital tract infection</strong> – Genital tract infection is the single most common identifiable risk factor for PPROM. Three lines of epidemiologic evidence strongly support this association: (1) patients with PPROM are significantly more likely than those with intact membranes to have pathogenic microorganisms in the amniotic fluid, (2) patients with PPROM have a significantly higher rate of histologic chorioamnionitis than those who deliver preterm without PPROM, and (3) the frequency of PPROM is significantly higher in patients with certain lower genital tract infections (particularly bacterial vaginosis) than in uninfected patients [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">The association between bacterial colonization of the lower genital tract and PPROM is not surprising. Many of the microorganisms that colonize the lower genital tract have the capacity to produce phospholipases, which can stimulate the production of prostaglandins and thereby lead to the onset of uterine contractions. In addition, the host's immune response to bacterial invasion of the endocervix and/or fetal membranes leads to the production of multiple inflammatory mediators that can cause localized weakening of the fetal membranes and result in PPROM [<a href="#rid7">7</a>]. Genetic regulation of the host's immune and inflammatory responses appears to play a role in susceptibility and response to infections associated with PPROM. (See  <a class="medical medical_review" href="/d/html/6785.html" rel="external">"Spontaneous preterm birth: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Previous PPROM</strong> – Studies have consistently reported that a history of PPROM is a strong risk factor for recurrence. As an example, the Preterm Prediction Study, a large prospective study conducted by the National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network, observed that patients with a history of PPROM leading to preterm birth had a threefold higher frequency of PPROM in a subsequent pregnancy compared with those with no such history (13.5 versus 4.1 percent, relative risk [RR] 3.3, 95% CI 2.1-5.2) [<a href="#rid8">8</a>]. Moreover, in the subsequent pregnancy, patients with a history of PPROM leading to preterm birth were at high risk of PPROM and preterm birth before 28 weeks (1.8 versus 0.13 percent in patients with no history of preterm birth due to PPROM, RR 13.5, 95% CI 23.0-80.3). Others have reported recurrence rates as high as 32 percent [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antepartum bleeding</strong> – First trimester vaginal bleeding is associated with a small but statistically significant increase in the risk of PPROM [<a href="#rid10">10</a>]. Antepartum bleeding in more than one trimester increases the risk of PPROM three- to sevenfold [<a href="#rid6">6,11,12</a>]. </p><p></p><p class="bulletIndent1">The development of PPROM in the setting of bleeding from abruption may be related to the high decidual concentration of tissue thromboplastin factor (also known as tissue factor III). In addition to its hemostatic properties, thrombin binds to decidual protease-activated receptors (PAR1 and 3) that up-regulate the expression of proteases such as matrix metalloproteases, which, in turn, degrade membranes. (See <a class="local">'Pathogenesis'</a> above and  <a class="medical medical_review" href="/d/html/6785.html" rel="external">"Spontaneous preterm birth: Pathogenesis", section on '#3 Decidual hemorrhage'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cigarette smoking</strong> – The risk of PPROM among smokers is increased two- to fourfold compared with nonsmokers. The risk persists even after adjustment for known confounders. The mechanism for the association is unclear. (See  <a class="medical medical_review" href="/d/html/4803.html" rel="external">"Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate"</a>.)</p><p></p><p>In addition, polyhydramnios, acute abdominal trauma (eg, from a motor vehicle collision, accidental fall, or domestic violence), and several polymorphisms of genes related to infection, inflammation, and collagen degradation have been identified as risk factors for PPROM.</p><p class="headingAnchor" id="H450397416"><span class="h1">CLINICAL FINDINGS</span></p><p class="headingAnchor" id="H450397533"><span class="h2">Patient presentation</span><span class="headingEndMark"> — </span>The classic clinical presentation of PPROM is a sudden "gush" of clear or pale yellow fluid from the vagina that soaks through clothes. However, many patients describe only leaking small amounts of fluid either continuously or intermittently, and some just report a sensation of abnormal wetness of the vagina or perineum. </p><p class="headingAnchor" id="H450397591"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>For patients who are not in active labor, examination of the cervix and vagina should be performed using a sterile speculum. Digital examination should be avoided because it may increase the risk of intrauterine infection and thus decrease the latency period (ie, time from PPROM to delivery) [<a href="#rid13">13-15</a>]. </p><p>Direct observation of amniotic fluid leaking from the cervical os and pooling in the vaginal vault is diagnostic of PPROM. If amniotic fluid is not immediately visible, the patient can be asked to push on their fundus, Valsalva, or cough to provoke leakage of amniotic fluid from the cervical os. </p><p>The cervix may appear dilated and/or effaced, and rarely, prolapse of a fetal part or the umbilical cord may be observed.</p><p class="headingAnchor" id="H450397685"><span class="h2">Ultrasonography</span><span class="headingEndMark"> — </span>Many, if not most, patients have amniotic fluid volume that is less than expected for gestational age. Criteria for oligohydramnios vary slightly among sonographers but can be defined as a maximum vertical pocket (MVP, also called single deepest pocket [SDP]) of amniotic fluid &lt;2 cm or an amniotic fluid index (AFI) ≤5 cm (some use ≤2 cm and &lt;5 cm, respectively). (See  <a class="medical medical_review" href="/d/html/462.html" rel="external">"Assessment of amniotic fluid volume", section on 'Semiquantitative techniques'</a>.)</p><p>In a prospective study of 290 singleton pregnancies with PPROM at 24 to 34 weeks of gestation, 67 percent had an AFI &lt;5 cm, and 47 percent had an MVP &lt;2 cm [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H4001133738"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>Hematology and chemistry tests are normal in the absence of infection or other complications of pregnancy. Laboratory tests to identify amniotic fluid are described below. (See <a class="local">'Laboratory tests'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSTIC EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H4184602765"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>We base the diagnosis of PPROM primarily on characteristic findings on both history and physical examination: a pregnant patient presents with a history of leaking fluid, and on sterile speculum examination, pooling of amniotic fluid in the posterior vaginal vault is observed. Pooling is the gold standard for diagnosis. If pooling is not observed, asking the patient to press on their fundus, cough, and bear down can enhance flow of amniotic fluid from the cervical os and confirm the diagnosis.</p><p>If pooling is still not seen, the author performs an ultrasound examination to assess amniotic fluid volume. In the author's practice, in a patient with a characteristic history of leaking fluid: </p><p class="bulletIndent1"><span class="glyph">●</span>Oligohydramnios (defined by an amniotic fluid index [AFI] ≤5 cm, maximum vertical pocket [MVP] &lt;2 cm, or subjective impression) is presumptive evidence of PROM, so no additional diagnostic testing is performed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the amniotic fluid volume is low normal (defined as an AFI 6 or 7 cm or by subjective impression) or normal (eg, by an AFI &gt;7 cm or subjective impression), the author orders one of the commercial tests for detecting amniotic fluid (see <a class="local">'Commercial tests'</a> below) and uses the result to confirm or exclude the diagnosis of PROM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the amniotic fluid volume is high (defined by an AFI &gt;24 cm, MVP ≥8 cm, or subjective impression), this finding almost always excludes the diagnosis of PPROM. The patient is discharged home if not in labor and given instructions to call if leaking recurs. (See  <a class="medical medical_review" href="/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations"</a>.)</p><p></p><p>Access to ultrasound is readily available to most clinicians and the examination also provides information about fetal status. The author no longer performs nitrazine paper or fern tests, primarily because of the possibility of false-positive results that could lead to inappropriate clinical decisions. Moreover, some facilities no longer permit clinicians to perform these tests because of quality assurance and compliance issues. (See <a class="local">'Nitrazine and fern tests'</a> below.)</p><p class="headingAnchor" id="H450398268"><span class="h2">Laboratory tests</span></p><p class="headingAnchor" id="H512513879"><span class="h3">Commercial tests</span><span class="headingEndMark"> — </span>The author bases the choice of commercial test on cost and the ease of performance in an individual hospital laboratory. Several tests for diagnosis of PROM are now commercially available. A 2013 meta-analysis of prospective observational or cohort studies investigating insulin-like growth factor binding protein 1 (IGFBP-1 [Actim PROM]) and placental alpha microglobulin-1 protein assay (PAMG-1 [AmniSure]) for diagnosis of rupture of membranes concluded PAMG-1 (AmniSure) was more accurate than IGFBP-1 (Actim PROM) for diagnosis of rupture of membranes in all patient populations (eg, known rupture status, uncertain rupture status) [<a href="#rid17">17</a>]. A subsequent randomized trial reported similar findings [<a href="#rid18">18</a>]. </p><p>Health care providers using these tests should be aware of their limitations, which are listed in the manufacturer's instructions, and use them as one component of the overall clinical assessment for PPROM (eg, history, speculum examination, ultrasound findings) [<a href="#rid19">19</a>]. There are no data to indicate that the performance of these tests varies across pregnancy.</p><p class="headingAnchor" id="H450398290"><span class="h4">PAMG-1 (AmniSure)</span><span class="headingEndMark"> — </span>AmniSure is a rapid slide test that uses immunochromatography to detect trace amounts of placental alpha microglobulin-1 protein in vaginal fluid. Placental alpha microglobulin-1 is released from decidual cells. The test is not affected by semen or trace amounts of blood.</p><p>The test is designed to be performed by the provider at the point of care using a commercially available kit but can be performed in the hospital laboratory if clinician credentialing is a concern. A sterile swab is inserted into the vagina for one minute, then placed into a vial containing a solvent for one minute, and then an AmniSure test strip is dipped into the vial. The test result is revealed by the presence of one or two lines within the next 5 to 10 minutes (one visible line means a negative result for amniotic fluid, two visible lines is a positive result, and no visible lines is an invalid result). </p><p>In large studies, sensitivity ranged from 94.4 to 98.9 percent, and specificity ranged from 87.5 to 100 percent [<a href="#rid20">20-24</a>]. In one study, the authors hypothesized that false-positive results in three patients might have been due to a small leak that sealed over [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H450398301"><span class="h4">IGFBP-1 (Actim PROM)</span><span class="headingEndMark"> — </span>IGFBP-1, also called placental protein 12 (PP12), is secreted by decidual and placental cells and has a very high concentration in amniotic fluid compared with other bodily fluids. An easy-to-use immunochromatography dipstick method (eg, Actim PROM) is available in some countries for use at the bedside to detect IGFBP-1 in vaginal secretions but can be performed in the hospital laboratory if clinician credentialing is a concern. A positive test is denoted by the presence of two blue lines on the dipstick. The test is not affected by the presence of bacteria in vaginal secretions, urine, semen, or small amounts of blood. </p><p>Sensitivity ranges from 95 to 100 percent, specificity ranges from 93 to 98 percent, and positive predictive value approaches 98 percent [<a href="#rid23">23,25-28</a>]. The test is most accurate when performed as soon as possible after PROM. </p><p class="headingAnchor" id="H2697491175"><span class="h4">Placental protein 12 and alpha-fetoprotein (ROM Plus)</span><span class="headingEndMark"> — </span>A combination monoclonal/polyclonal antibody test for diagnosis of PPROM detects two protein markers found in amniotic fluid: PP12 (also called IGFBP-1) and alpha-fetoprotein (AFP). The test is performed by placing the ROM Plus test swab in the vagina for 15 seconds, placing the swab in a diluent, and then placing a sample of the diluent on a special test strip, which develops a line if the proteins are present. Trace amounts of blood do not affect the test.</p><p>A multicenter prospective observational study that compared the accuracy of this point-of-care test with conventional clinical assessment (speculum examination plus both fern and nitrazine tests) for diagnosis of rupture of membranes in 285 patients at 15 to 42 weeks of gestation found that the immunoassay had higher sensitivity (99 versus 85 percent) and lower specificity (91 versus 98 percent) [<a href="#rid29">29</a>]. A limitation of this study was that confirmation of PROM was based on review of the medical records following delivery.</p><p class="headingAnchor" id="H1664194520"><span class="h3">Nitrazine and fern tests</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitrazine</strong> – Nitrazine paper is used to test the pH of vaginal fluid. Nitrazine (or phenaphthazine) is a pH indicator dye that indicates pH in the 4.5 to 7.5 range. Amniotic fluid usually has a pH range of 7.0 to 7.3, which is different from the normal vaginal pH of 3.8 to 4.2 and usually different from the pH of urine, which is typically &lt;6.0 but may be higher  (<a class="graphic graphic_picture graphicRef56755" href="/d/graphic/56755.html" rel="external">picture 1</a>) [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1">False-negative and false-positive nitrazine test results occur in up to 5 percent of cases [<a href="#rid31">31,32</a>]. False-negative test results can occur when leaking is intermittent or the amniotic fluid is diluted by other vaginal fluids. False-positive results can be due to the presence of alkaline fluids in the vagina, such as blood, seminal fluid, or soap. In addition, the pH of urine can be elevated to near 8 if infected with <em>Proteus</em> species.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fern</strong> – Dried amniotic fluid shows an arborization (ferning) pattern when viewed under a microscope. Fluid from the posterior vaginal fornix is swabbed onto a glass slide and allowed to dry for at least 10 minutes. Amniotic fluid produces a delicate ferning pattern, in contrast to the thick and wide arborization pattern of dried cervical mucus  (<a class="graphic graphic_picture graphicRef78666" href="/d/graphic/78666.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef61431" href="/d/graphic/61431.html" rel="external">picture 3</a>). </p><p></p><p class="bulletIndent1">Well-estrogenized cervical mucus or a fingerprint on the microscope slide may cause a false-positive fern test; false negatives can be due to inadequate amniotic fluid on the swab or heavy contamination with vaginal discharge or blood.</p><p></p><p class="headingAnchor" id="H1472250124"><span class="h3">Home tests</span><span class="headingEndMark"> — </span>In the United Kingdom, an absorbent pad (AmnioSense) that changes color at pH &gt;5.2 is used as a panty liner and marketed to pregnant people. Vaginal flora (eg, <em>Candida albicans</em>) may cause false-positive results [<a href="#rid33">33</a>].</p><p>The manufacturer cites sensitivity and specificity of 95.8 and 87 percent, respectively, compared with standard clinical diagnosis [<a href="#rid34">34</a>]. In a study of 139 pregnant people, the sensitivity and specificity of this device for diagnosis of membrane rupture were 98 and 65 percent, respectively (95% CI 91-100 and 54-75, respectively) [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2188702764"><span class="h3">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Instillation of dye (tampon test)</strong> – This invasive test has been replaced by commercial noninvasive tests. It can be challenging to perform when amniotic fluid volume is severely reduced, and can cause rupture of membranes if the membranes are intact. (See <a class="local">'Commercial tests'</a> above.)</p><p></p><p class="bulletIndent1">In the past, clinicians performed the "tampon test" in problematic cases. Under ultrasound guidance, 1 mL of <a class="drug drug_general" data-topicid="9088" href="/d/drug information/9088.html" rel="external">indigo carmine</a> dye in 9 mL of sterile <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> was injected transabdominally into the amniotic fluid, and a tampon was placed in the vagina. Twenty minutes later, the tampon was removed and examined for blue staining, which indicated leakage of amniotic fluid. It should be noted that maternal urine will also stain blue and should not be mistaken for amniotic fluid. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9088" href="/d/drug information/9088.html" rel="external">Indigo carmine</a> dye is no longer readily available in the United States. Possible alternatives to indigo carmine include sodium <a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">fluorescein</a> and phenolsulfonphthalein (where available) [<a href="#rid35">35</a>]. </p><p></p><p class="headingAnchor" id="H6"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Other causes of vaginal/perineal wetness include urinary incontinence, excessive vaginal discharge (normal or related to infection), cervical mucus, and perspiration. These entities can be distinguished by differences in their characteristics.</p><p class="bulletIndent1"><span class="glyph">●</span>Characteristics of amniotic fluid:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The appearance of amniotic fluid (clear or pale yellow) can be similar to that of urine, but amniotic fluid is odorless (in the absence of infection). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Amniotic fluid leakage is continuous or intermittent, whereas bladder leakage should cease after the bladder is emptied and kept at low volume. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Amniotic fluid usually has a pH range of 7.0 to 7.3, which is different from the normal vaginal pH of 3.8 to 4.2 and usually different from the pH of urine, which is typically &lt;6.0 but may be higher  (<a class="graphic graphic_picture graphicRef56755" href="/d/graphic/56755.html" rel="external">picture 1</a>) [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Amniotic fluid and urine have different chemical compositions (urine has higher creatinine and urea levels [<a href="#rid36">36</a>]), but such testing is rarely indicated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Characteristics of vaginal discharge:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vaginal discharge may be clear or yellow, similar to amniotic fluid and urine, but it is generally thick, not watery, and has distinct findings  (<a class="graphic graphic_table graphicRef68759" href="/d/graphic/68759.html" rel="external">table 2</a>) that distinguish it from these other substances. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perspiration may result in perineal wetness, but it is not accompanied by pooling in the vagina. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical mucus is clear and has a high pH (7) like amniotic fluid, but no more than a small amount pools in the vagina and leakage is self-limited. It has a thick and wide arborization pattern  (<a class="graphic graphic_picture graphicRef78666" href="/d/graphic/78666.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef61431" href="/d/graphic/61431.html" rel="external">picture 3</a>) in contrast to the delicate ferning pattern of amniotic fluid. (See <a class="local">'Nitrazine and fern tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A reduction of amniotic fluid volume on ultrasound is a nonspecific finding related to many etiologies, including PPROM, but these etiologies (eg, abnormality of the fetal kidney/urinary tract, fetal growth restriction) are not associated with leaking and have other fetal findings. (See  <a class="medical medical_review" href="/d/html/462.html" rel="external">"Assessment of amniotic fluid volume"</a>.)</p><p></p><p class="headingAnchor" id="H2607216152"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>Cessation of fluid leakage is rare, except in patients with PPROM related to amniocentesis. Sealing of membranes is associated with a more favorable prognosis [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/5390.html" rel="external">"Diagnostic amniocentesis", section on 'Leakage of amniotic fluid'</a>.) </p><p>The duration of the latency period (ie, time from PROM to delivery) inversely correlates with gestational age at membrane rupture and is shorter in cases with residual oligohydramnios [<a href="#rid38">38</a>]. Nevertheless, the majority of pregnancies with PPROM deliver within one week of membrane rupture. In a randomized trial of 239 group B streptococcus-negative patients with PPROM at 24 to 32 weeks managed expectantly with prophylactic antibiotics, the median time to delivery was 6.1 days; the cumulative delivery rate was 27 percent within 48 hours, 56 percent within 7 days, 76 percent within 14 days, and 86 percent within 21 days [<a href="#rid39">39,40</a>]. Among the minority of patients who did not deliver within this timeframe, one had a latency period of 59 days. </p><p>In the absence of spontaneous labor, delivery timing depends on occurrence of complications that would prompt delivery or gestational age ≥34 weeks. Antepartum management and timing of delivery are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/120959.html" rel="external">"Preterm prelabor rupture of membranes: Management and outcome", section on 'Timing of delivery'</a>.)</p><p class="headingAnchor" id="H3911333084"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>The fetus and neonate are at greater risk of PPROM-related morbidity and mortality than the mother  (<a class="graphic graphic_table graphicRef88802" href="/d/graphic/88802.html" rel="external">table 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chorioamnionitis</strong> – Chorioamnionitis has been reported in up to 60 percent of cases and is a common reason for induction or initiation of spontaneous labor [<a href="#rid41">41</a>]. Clinical chorioamnionitis is increased twofold in cases with residual oligohydramnios [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abruption</strong> – Placental abruption occurs in 2 to 5 percent of pregnancies complicated by PPROM [<a href="#rid42">42-45</a>]. The risk is increased seven- to ninefold in PPROM pregnancies complicated by intrauterine infection or oligohydramnios [<a href="#rid43">43,44</a>]. Placental abruption may be the precipitating event for, or a consequence of, PPROM. (See  <a class="medical medical_review" href="/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences", section on 'Pathophysiology'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> –<strong> </strong>Fetal malpresentation is common, given the preterm gestational age and the frequent occurrence of reduced amniotic fluid volume. Noncephalic presentation may increase the risk of cord prolapse, abruption, infection, and fetal demise [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1">The risk of cord prolapse is especially high (11 percent in one study [<a href="#rid47">47</a>]) in the setting of both noncephalic fetal presentation and PPROM. (See  <a class="medical medical_review" href="/d/html/4461.html" rel="external">"Umbilical cord prolapse"</a> and  <a class="medical medical_review" href="/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"</a>.) </p><p></p><p class="headingAnchor" id="H151730957"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117941.html" rel="external">"Society guideline links: Prelabor rupture of membranes"</a>.)</p><p class="headingAnchor" id="H13301244"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/82972.html" rel="external">"Patient education: Preterm prelabor rupture of membranes (The Basics)"</a>) </p><p></p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology and epidemiology</strong> – Preterm prelabor rupture of membranes (PPROM) refers to rupture of fetal membranes prior to onset of labor in pregnancies &lt;37+0 weeks. It occurs in 3 percent of pregnancies. PPROM is the most common identifiable cause of preterm birth and responsible for one-third of such births. (See <a class="local">'Introduction'</a> above and <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Genital tract infection, a history of PPROM in a previous pregnancy, antepartum bleeding, and cigarette smoking have a particularly strong association with PPROM. PPROM in a previous pregnancy is associated with at least a threefold increase in risk of PPROM in the subsequent pregnancy. Other important risk factors include polyhydramnios and abdominal trauma. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of PPROM is clinical, based on visualization of amniotic fluid coming out of the cervical canal/pooling in the posterior vaginal fornix of a patient who presents with a history of leaking fluid. In the absence of pooling, we suggest an ultrasound examination as the next step in the diagnostic evaluation  (<a class="graphic graphic_algorithm graphicRef121098" href="/d/graphic/121098.html" rel="external">algorithm 1</a>). In a patient with a characteristic history of leaking fluid (see <a class="local">'Our approach'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the absence of another obvious cause such as fetal urinary tract obstruction, oligohydramnios is presumptive evidence of PROM, so no additional diagnostic testing is performed. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the amniotic fluid index (AFI) is low normal or normal, the author orders one of the commercial tests for detecting amniotic fluid in the vagina and uses the result to confirm or exclude the diagnosis of PROM. (See <a class="local">'Commercial tests'</a> above.)</p><p></p><p class="bulletIndent2">Checking pH and arborization ("nitrazine and fern") on a sample from the posterior vaginal fornix is an acceptable alternative. However, these tests can be misleading in the setting of bleeding, highly estrogenized cervical mucus, and a urinary tract infection due to <em>Proteus </em>species. (See <a class="local">'Nitrazine and fern tests'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the AFI is high (polyhydramnios), this finding almost always excludes the diagnosis of PPROM. The patient is discharged home if not in labor and given instructions to call if leaking recurs. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Other causes of vaginal/perineal wetness include urinary incontinence, excessive vaginal discharge (normal or related to infection), cervical mucus, and perspiration. These diagnoses can be excluded by history, physical examination, sonography, and laboratory testing for amniotic fluid. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cessation of fluid leakage is rare, except in patients with PPROM related to amniocentesis. Sealing of membranes is associated with a more favorable prognosis. (See <a class="local">'Clinical course'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The duration of the latency period (ie, time from PROM to delivery) inversely correlates with gestational age at membrane rupture; however, the majority of pregnancies with PPROM deliver within one week of membrane rupture. In the absence of spontaneous labor, delivery timing depends on occurrence of complications that would prompt delivery or gestational age ≥34 weeks. (See <a class="local">'Clinical course'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The fetus and neonate are at greater risk of PPROM-related morbidity and mortality than the mother  (<a class="graphic graphic_table graphicRef88802" href="/d/graphic/88802.html" rel="external">table 3</a>). In the absence of spontaneous labor, complications that should prompt delivery include chorioamnionitis, placental abruption, and fetal heart rate abnormalities suggesting cord prolapse or compromise. (See <a class="local">'Complications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstet Gynecol Clin North Am 2005; 32:411.</a></li><li class="breakAll">Jantien L van der Heyden. Preterm prelabor rupture of membranes:  different gestational ages, different problems. Thesis. 2014.</li><li><a class="nounderline abstract_t">Smith G, Rafuse C, Anand N, et al. Prevalence, management, and outcomes of preterm prelabour rupture of the membranes of women in Canada. J Obstet Gynaecol Can 2005; 27:547.</a></li><li><a class="nounderline abstract_t">Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7:728.</a></li><li><a class="nounderline abstract_t">Kumar D, Moore RM, Mercer BM, et al. The physiology of fetal membrane weakening and rupture: Insights gained from the determination of physical properties revisited. Placenta 2016; 42:59.</a></li><li><a class="nounderline abstract_t">Harger JH, Hsing AW, Tuomala RE, et al. Risk factors for preterm premature rupture of fetal membranes: a multicenter case-control study. Am J Obstet Gynecol 1990; 163:130.</a></li><li><a class="nounderline abstract_t">Parry S, Strauss JF 3rd. Premature rupture of the fetal membranes. N Engl J Med 1998; 338:663.</a></li><li><a class="nounderline abstract_t">Mercer BM, Goldenberg RL, Moawad AH, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999; 181:1216.</a></li><li><a class="nounderline abstract_t">Asrat T, Lewis DF, Garite TJ, et al. Rate of recurrence of preterm premature rupture of membranes in consecutive pregnancies. Am J Obstet Gynecol 1991; 165:1111.</a></li><li><a class="nounderline abstract_t">Lykke JA, Dideriksen KL, Lidegaard O, Langhoff-Roos J. First-trimester vaginal bleeding and complications later in pregnancy. Obstet Gynecol 2010; 115:935.</a></li><li><a class="nounderline abstract_t">Ekwo EE, Gosselink CA, Woolson R, Moawad A. Risks for premature rupture of amniotic membranes. Int J Epidemiol 1993; 22:495.</a></li><li><a class="nounderline abstract_t">Berkowitz GS, Blackmore-Prince C, Lapinski RH, Savitz DA. Risk factors for preterm birth subtypes. Epidemiology 1998; 9:279.</a></li><li><a class="nounderline abstract_t">Alexander JM, Mercer BM, Miodovnik M, et al. The impact of digital cervical examination on expectantly managed preterm rupture of membranes. Am J Obstet Gynecol 2000; 183:1003.</a></li><li><a class="nounderline abstract_t">Schutte MF, Treffers PE, Kloosterman GJ, Soepatmi S. Management of premature rupture of membranes: the risk of vaginal examination to the infant. Am J Obstet Gynecol 1983; 146:395.</a></li><li><a class="nounderline abstract_t">Imseis HM, Trout WC, Gabbe SG. The microbiologic effect of digital cervical examination. Am J Obstet Gynecol 1999; 180:578.</a></li><li><a class="nounderline abstract_t">Mercer BM, Rabello YA, Thurnau GR, et al. The NICHD-MFMU antibiotic treatment of preterm PROM study: impact of initial amniotic fluid volume on pregnancy outcome. Am J Obstet Gynecol 2006; 194:438.</a></li><li><a class="nounderline abstract_t">Ramsauer B, Vidaeff AC, Hösli I, et al. The diagnosis of rupture of fetal membranes (ROM): a meta-analysis. J Perinat Med 2013; 41:233.</a></li><li><a class="nounderline abstract_t">Liang DK, Qi HB, Luo X, et al. Comparative study of placental α-microglobulin-1, insulin-like growth factor binding protein-1 and nitrazine test to diagnose premature rupture of membranes: a randomized controlled trial. J Obstet Gynaecol Res 2014; 40:1555.</a></li><li class="breakAll">Health care providers using rupture of membranes tests should be aware of test limitations listed within manufacturer instructions and use them as part (Accessed on August 09, 2018).</li><li><a class="nounderline abstract_t">Cousins LM, Smok DP, Lovett SM, Poeltler DM. AmniSure placental alpha microglobulin-1 rapid immunoassay versus standard diagnostic methods for detection of rupture of membranes. Am J Perinatol 2005; 22:317.</a></li><li><a class="nounderline abstract_t">Lee SE, Park JS, Norwitz ER, et al. Measurement of placental alpha-microglobulin-1 in cervicovaginal discharge to diagnose rupture of membranes. Obstet Gynecol 2007; 109:634.</a></li><li><a class="nounderline abstract_t">Abdelazim IA, Makhlouf HH. Placental alpha microglobulin-1 (AmniSure(®) test) for detection of premature rupture of fetal membranes. Arch Gynecol Obstet 2012; 285:985.</a></li><li><a class="nounderline abstract_t">Marcellin L, Anselem O, Guibourdenche J, et al. [Comparison of two bedside tests performed on cervicovaginal fluid to diagnose premature rupture of membranes]. J Gynecol Obstet Biol Reprod (Paris) 2011; 40:651.</a></li><li><a class="nounderline abstract_t">Birkenmaier A, Ries JJ, Kuhle J, et al. Placental α-microglobulin-1 to detect uncertain rupture of membranes in a European cohort of pregnancies. Arch Gynecol Obstet 2012; 285:21.</a></li><li><a class="nounderline abstract_t">Akercan F, Cirpan T, Kazandi M, et al. The value of the insulin-like growth factor binding protein-1 in the cervical-vaginal secretion detected by immunochromatographic dipstick test in the prediction of delivery in women with clinically unconfirmed preterm premature rupture of membranes. Eur J Obstet Gynecol Reprod Biol 2005; 121:159.</a></li><li><a class="nounderline abstract_t">Darj E, Lyrenäs S. Insulin-like growth factor binding protein-1, a quick way to detect amniotic fluid. Acta Obstet Gynecol Scand 1998; 77:295.</a></li><li><a class="nounderline abstract_t">Erdemoglu E, Mungan T. Significance of detecting insulin-like growth factor binding protein-1 in cervicovaginal secretions: comparison with nitrazine test and amniotic fluid volume assessment. Acta Obstet Gynecol Scand 2004; 83:622.</a></li><li><a class="nounderline abstract_t">Gaucherand P, Salle B, Sergeant P, et al. Comparative study of three vaginal markers of the premature rupture of membranes. Insulin like growth factor binding protein 1 diamine-oxidase pH. Acta Obstet Gynecol Scand 1997; 76:536.</a></li><li><a class="nounderline abstract_t">Thomasino T, Levi C, Draper M, Neubert AG. Diagnosing rupture of membranes using combination monoclonal/polyclonal immunologic protein detection. J Reprod Med 2013; 58:187.</a></li><li><a class="nounderline abstract_t">Seeds AE, Hellegers AE. Acid-base determinations in human amniotic fluid throughout pregnancy. Am J Obstet Gynecol 1968; 101:257.</a></li><li><a class="nounderline abstract_t">Abe T. The detection of rupture of fetal membranes with the nitrazine indicator. Am J Obstet Gynecol 1940; 39:400.</a></li><li><a class="nounderline abstract_t">Davidson KM. Detection of premature rupture of the membranes. Clin Obstet Gynecol 1991; 34:715.</a></li><li><a class="nounderline abstract_t">Mulhair L, Carter J, Poston L, et al. Prospective cohort study investigating the reliability of the AmnioSense method for detection of spontaneous rupture of membranes. BJOG 2009; 116:313.</a></li><li class="breakAll">https://www.amniosense.co.uk/res/Detail%20Aid.pdf (Accessed on April 09, 2019).</li><li><a class="nounderline abstract_t">Ireland KE, Rodriguez EI, Acosta OM, Ramsey PS. Intra-amniotic Dye Alternatives for the Diagnosis of Preterm Prelabor Rupture of Membranes. Obstet Gynecol 2017; 129:1040.</a></li><li><a class="nounderline abstract_t">Mitchell G, Field B, Kerr C. Biochemical differences between amniotic fluid and maternal urine. Br Med J 1977; 1:811.</a></li><li><a class="nounderline abstract_t">Johnson JW, Egerman RS, Moorhead J. Cases with ruptured membranes that "reseal". Am J Obstet Gynecol 1990; 163:1024.</a></li><li><a class="nounderline abstract_t">Pergialiotis V, Bellos I, Fanaki M, et al. The impact of residual oligohydramnios following preterm premature rupture of membranes on adverse pregnancy outcomes: a meta-analysis. Am J Obstet Gynecol 2020; 222:628.</a></li><li><a class="nounderline abstract_t">Melamed N, Hadar E, Ben-Haroush A, et al. Factors affecting the duration of the latency period in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2009; 22:1051.</a></li><li><a class="nounderline abstract_t">Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997; 278:989.</a></li><li><a class="nounderline abstract_t">Beydoun SN, Yasin SY. Premature rupture of the membranes before 28 weeks: conservative management. Am J Obstet Gynecol 1986; 155:471.</a></li><li><a class="nounderline abstract_t">Williams MA, Lieberman E, Mittendorf R, et al. Risk factors for abruptio placentae. Am J Epidemiol 1991; 134:965.</a></li><li><a class="nounderline abstract_t">Vintzileos AM, Campbell WA, Nochimson DJ, Weinbaum PJ. Preterm premature rupture of the membranes: a risk factor for the development of abruptio placentae. Am J Obstet Gynecol 1987; 156:1235.</a></li><li><a class="nounderline abstract_t">Ananth CV, Oyelese Y, Srinivas N, et al. Preterm premature rupture of membranes, intrauterine infection, and oligohydramnios: risk factors for placental abruption. Obstet Gynecol 2004; 104:71.</a></li><li><a class="nounderline abstract_t">Major CA, de Veciana M, Lewis DF, Morgan MA. Preterm premature rupture of membranes and abruptio placentae: is there an association between these pregnancy complications? Am J Obstet Gynecol 1995; 172:672.</a></li><li><a class="nounderline abstract_t">Goodman JR, Lambert AE, Peck JD, et al. Outcomes in cephalic vs noncephalic presentation in the setting of preterm premature rupture of membranes. Am J Obstet Gynecol 2013; 208:231.e1.</a></li><li><a class="nounderline abstract_t">Lewis DF, Robichaux AG, Jaekle RK, et al. Expectant management of preterm premature rupture of membranes and nonvertex presentation: what are the risks? Am J Obstet Gynecol 2007; 196:566.e1.</a></li></ol></div><div id="topicVersionRevision">Topic 6754 Version 126.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125041" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Preterm premature rupture of the membranes: current approaches to evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125041" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Preterm premature rupture of the membranes: current approaches to evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100631" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence, management, and outcomes of preterm prelabour rupture of the membranes of women in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8573349" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Proteolytic remodeling of extracellular matrix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27238715" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The physiology of fetal membrane weakening and rupture: Insights gained from the determination of physical properties revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2197863" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk factors for preterm premature rupture of fetal membranes: a multicenter case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486996" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Premature rupture of the fetal membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561648" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951524" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rate of recurrence of preterm premature rupture of membranes in consecutive pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410766" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : First-trimester vaginal bleeding and complications later in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8359967" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risks for premature rupture of amniotic membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9583419" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk factors for preterm birth subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035354" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The impact of digital cervical examination on expectantly managed preterm rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859160" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Management of premature rupture of membranes: the risk of vaginal examination to the infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10076131" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The microbiologic effect of digital cervical examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458643" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The NICHD-MFMU antibiotic treatment of preterm PROM study: impact of initial amniotic fluid volume on pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23314505" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The diagnosis of rupture of fetal membranes (ROM): a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24888915" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparative study of placentalα-microglobulin-1, insulin-like growth factor binding protein-1 and nitrazine test to diagnose premature rupture of membranes: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24888915" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparative study of placentalα-microglobulin-1, insulin-like growth factor binding protein-1 and nitrazine test to diagnose premature rupture of membranes: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16118720" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : AmniSure placental alpha microglobulin-1 rapid immunoassay versus standard diagnostic methods for detection of rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329514" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Measurement of placental alpha-microglobulin-1 in cervicovaginal discharge to diagnose rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22037683" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Placental alpha microglobulin-1 (AmniSure(®) test) for detection of premature rupture of fetal membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22005046" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : [Comparison of two bedside tests performed on cervicovaginal fluid to diagnose premature rupture of membranes].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475966" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Placentalα-microglobulin-1 to detect uncertain rupture of membranes in a European cohort of pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054956" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The value of the insulin-like growth factor binding protein-1 in the cervical-vaginal secretion detected by immunochromatographic dipstick test in the prediction of delivery in women with clinically unconfirmed preterm premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9539275" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Insulin-like growth factor binding protein-1, a quick way to detect amniotic fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15225185" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Significance of detecting insulin-like growth factor binding protein-1 in cervicovaginal secretions: comparison with nitrazine test and amniotic fluid volume assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9246958" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparative study of three vaginal markers of the premature rupture of membranes. Insulin like growth factor binding protein 1 diamine-oxidase pH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23763001" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnosing rupture of membranes using combination monoclonal/polyclonal immunologic protein detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5652958" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acid-base determinations in human amniotic fluid throughout pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The detection of rupture of fetal membranes with the nitrazine indicator</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1778013" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Detection of premature rupture of the membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18652589" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prospective cohort study investigating the reliability of the AmnioSense method for detection of spontaneous rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18652589" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prospective cohort study investigating the reliability of the AmnioSense method for detection of spontaneous rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486367" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intra-amniotic Dye Alternatives for the Diagnosis of Preterm Prelabor Rupture of Membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/66963" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Biochemical differences between amniotic fluid and maternal urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2206055" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cases with ruptured membranes that "reseal".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109463" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The impact of residual oligohydramnios following preterm premature rupture of membranes on adverse pregnancy outcomes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19900043" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Factors affecting the duration of the latency period in preterm premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9307346" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3752169" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Premature rupture of the membranes before 28 weeks: conservative management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951294" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Risk factors for abruptio placentae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3495181" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Preterm premature rupture of the membranes: a risk factor for the development of abruptio placentae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229003" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Preterm premature rupture of membranes, intrauterine infection, and oligohydramnios: risk factors for placental abruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7856704" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Preterm premature rupture of membranes and abruptio placentae: is there an association between these pregnancy complications?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23220269" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Outcomes in cephalic vs noncephalic presentation in the setting of preterm premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17547897" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Expectant management of preterm premature rupture of membranes and nonvertex presentation: what are the risks?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
